Allergy Development Update

RNS Number : 5381H

Omega Diagnostics Group PLC

21 June 2013

 



Omega Diagnostics Group PLC

("Omega" or the "Company")

Allergy Development Update

Omega (AIM:ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has finalised the specific allergy assay protocol for use with the IDS-iSYS platform. Following a design review meeting by its Allergy Project Team, the protocol which is now fixed for the remainder of the development programme has effectively eliminated the previously reported imprecision issues.

The Company will now begin the final claim support work for the first 10 allergens that have already been optimised.  As previously reported, sufficient patient serum samples are in stock to allow the optimisation work to begin with a further 30 allergens and the Company remains on track to launch with a panel of 40 tests by the end of the current financial year.

Commenting on the development update, Andrew Shepherd, Chief Executive, stated: "This is a crucial milestone in the development of our allergy assays on the IDS-iSYS platform. We now look forward to making further significant progress towards our projected launch date."

Contacts:

Omega Diagnostics Group PLC	Tel: [phone]
Andrew Shepherd, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
Jag Grewal, Group Sales and Marketing Director
finnCap Ltd	Tel: [phone]
Geoff Nash/Christopher Raggett (Corporate Finance)
Stephen Norcross/Mia Gardner (Corporate Broking)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

MSCBLGDLUBDBGXG